Commercial launch of Pivya (pivmecillinam) tablets - Alembic Ltd

Code BSE: 506235 NSE:

Alembic Pharmaceuticals Limited, has reported its first prescription-based sale in the United States of America (US) following the commercial launch of Pivya (pivmecillinam) tablets, an oral prescription antibiotic. Pivya represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women. The segment has seen limited new product introductions for more than a decade, creating an opportunity for a clinically established therapy with a strong safety and efficacy profile.